Skip to main content
DNTH logo

Dianthus Therapeutics, Inc.

DNTHNASDAQHealthcareBiotechnology

$74.39Today:- (-)1Y +106.64%

As of Oct 15, 2026 close

Market cap
$4.17B
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$32.22$117.88
Volume (live)
-
Avg. volume (3M)
904.33K

Dianthus Therapeutics (DNTH) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Dianthus Therapeutics used $129.06M of cash in operating activities and spent $213.00K on capital expenditures. That left free cash flow of −$129.27M.

Dianthus Therapeutics Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Dianthus Therapeutics, Inc. (DNTH) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income-162.34-84.97-43.56-28.48-71.14-74.94-76.77-57.52-35.49
Depreciation & Amortization0.110.410.360.032.021.981.840.880.38
Deferred Income Tax0.000.00-0.660.000.00-12.95-13.540.000.00
Stock Based Compensation22.7912.892.901.520.060.000.000.002.26
Change in Working Capital16.73-0.354.86-1.653.14-1.198.833.981.32
Change in Accounts Receivable0.760.005.16-4.16-1.010.000.000.000.00
Change in Accounts Payable11.288.190.662.28-0.720.950.152.50-1.13
Change in Other Working Capital0.12-8.54-0.96-0.66-0.96-2.138.691.482.44
Other Operating Activities-6.35-6.17-0.76-0.490.8023.0722.5310.0213.41
Net Cash from Operating Activities-129.06-78.18-36.86-29.07-9.90-64.02-57.10-41.89-22.26
Investing Activities
Capital Expenditures-0.21-0.11-0.11-0.14-0.03-0.40-3.06-7.67-2.20
Acquisitions0.000.000.000.000.000.000.000.010.00
Purchases of Investments-435.01-413.71-57.42-61.68-45.31-95.74-144.37-84.040.00
Sales/Maturities of Investments312.39127.0077.792.0090.0085.50148.960.000.00
Other Investing Activities0.000.000.000.000.000.000.000.01-0.14
Net Cash from Investing Activities-122.83-286.8120.25-59.82-0.03-10.641.53-91.70-2.20
Financing Activities
Common Stock Issued280.13269.2072.000.0089.6067.7462.30142.1571.49
Common Stock Repurchased0.000.000.000.000.000.000.00-0.09-0.21
Other Financing Activities-0.36-13.5861.57-3.32-0.090.000.000.000.00
Net Cash from Financing Activities280.13255.62133.5796.6814.9167.7462.30142.1571.49
Summary
Net Change in Cash28.23-109.37116.977.794.98-6.926.736.7847.02
Cash at Beginning of Period23.02132.3915.437.6458.1565.0758.3551.574.54
Cash at End of Period51.2523.02132.3915.43131.6558.1565.0758.3551.57
Free Cash Flow-129.27-78.29-36.97-29.21-9.94-64.42-60.16-49.56-24.46

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Dianthus Therapeutics Cash Flow

What is Dianthus Therapeutics's free cash flow?

Dianthus Therapeutics had negative free cash flow of $129.27M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$129.06M minus $213.00K of capital expenditures.

How much does Dianthus Therapeutics spend on capital expenditures?

Dianthus Therapeutics spent $213.00K on capital expenditures in fiscal 2025, compared with $105.00K a year earlier.

Does Dianthus Therapeutics pay dividends or buy back shares?

Dianthus Therapeutics's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition